Magnetic resonance–guided interstitial high-intensity focused ultrasound for brain tumor ablation

Jacquelyn MacDonell, MS,1,2 Niravkumar Patel, PhD,3 Sebastian Rubino, MD,1,2 Goutam Ghoshal, PhD,4 Gregory Fischer, PhD,3 E. Clif Burdette, PhD,4 Roy Hwang, MD,1 and Julie G. Pilitsis, MD, PhD1,2

Departments of 1Neuroscience and Experimental Therapeutics and 1Neurosurgery, Albany Medical Center, Albany, New York; 2Robotics Engineering Program, Worcester Polytechnic Institute, Worcester, Massachusetts; and 4Acoustic MedSystems, Inc., Savoy, Illinois

Currently, treatment of brain tumors is limited to resection, chemotherapy, and radiotherapy. Thermal ablation has been recently explored. High-intensity focused ultrasound (HIFU) is being explored as an alternative. Specifically, the authors propose delivering HiFU internally to the tumor with an MRI-guided robotic assistant (MRgRA). The advantage of the authors’ interstitial device over external MRI-guided HiFU (MRgHiFU) is that it allows for conformal, precise ablation and concurrent tissue sampling. The authors describe their workflow for MRgRA HiFU delivery.

https://thejns.org/doi/abs/10.3171/2017.11.FOCUS17613

KEY WORDS brain tumor; high-intensity focused ultrasound; neural ablation; MRI guided

The main goal of treatment of intracranial neoplasms is to eradicate tumor cells with minimal disruption of surrounding normal parenchyma. Stereotactic radiosurgery (SRS) has been used as one modality of treatment in appropriate cases. SRS is limited by the dose a patient can tolerate and adverse effects of radiation. These limitations provide a niche for alternative therapies. Furthermore, tissue samples cannot be obtained during treatment. Recently, thermal therapies including high-intensity focused ultrasound (HIFU) and laser interstitial thermal therapy (LITT) have been proposed as alternatives.20 HIFU has advanced significantly over the past several years, and with the advent of MRI-guided HIFU (MRgHiFU), noninvasive ablation is now possible. However, difficulties with penetration of the calvaria limit the use of HIFU in cases of superficial lesions. Additionally, ablation zones cannot be conformed to the tumor shape, and there is no ability to acquire tissue samples. In the present article, we propose a system that utilizes an intraparenchymal catheter to deliver HiFU therapy to treat intracranial neoplasms, and we describe the workflow as it relates to our swine model. We deliver HiFU through an MRI-guided robotic assistant (MRgRA) to improve efficiency and ergonomic issues.

Role of Thermal Energy in Brain Tumor Ablation

The treatment of brain metastasis is highly individualized based on tumor presentation. Factors such as tumor histology, size, and location relative to eloquent brain regions will determine what treatment options are available to patients. Currently, the standard of care for brain metastasis is limited to SRS, whole brain radiation therapy, and surgical resection.9,22,28 Each of these methods has limitations that result in debilitating side effects or disqualifies patients from treatment altogether.

Resection is generally only offered to patients with a single metastatic lesion that presents in noneloquent regions. Whole-brain radiation therapy is typically used in conjunction with other surgical therapies, and while it significantly reduces recurrence rates, it is accompanied by debilitating side effects such as radiation necrosis and leukoencephalopathy.1 Although SRS attempts to reduce...
radiation toxicity by targeting the metastases and avoiding surrounding tissue, 84% of patients will present with leukoencephalopathy within 4 years.7 Thermal ablative alternatives have been successfully applied to neurosurgical therapies, with HIFU used for the treatment of essential tremor and LITT for the treatment of epilepsy.3,7 Both require MRI thermometry (MRIT). These two therapies require the same workflow, but the mechanism behind which the thermal energy is generated differs, as does the distribution of energy.

MRI-guided LITT was first approved as an ablation therapy for intracranial lesions by the United States Food and Drug Administration in 2007, when it was initially used in the treatment of small brain tumors.13 Most applications are for focally contained, surgically inaccessible lesions, with some accessible lesions being treated as well. The benefit of LITT over conventional surgical removal is reduced healing time to expedite time to adjuvant chemotheraphy and radiation therapy. The physics of LITT are based on light absorption causing the release of thermal energy from a low-voltage laser; this thermal energy raises the temperature to 60°C, resulting in liquefactive necrosis. The characteristics of tumor versus normal parenchyma produce a demarcation in tissue absorption and therefore a steep temperature fall off in normal parenchyma. As a modality of treatment, studies suggest improved survival in patients with recurrent glioblastoma (GBM) and mixed results in those with metastatic brain tumors.21 Overall complications range from 20%–50%, with a major complication rate of <5%. LITT cannot be used in the vicinity of great vessels, or large hemorrhages.20,21

HIFU was first used in the treatment of brain tumors during the late 1960s and early 1970s.7 Since that time, modern HIFU treatment systems have evolved to include thermal ablation, intraprocedural anatomy- and temperature-sensitive MRI guidance, and the use of ultrasound phased arrays to correct for cranial distortion.11 The Insightec MRI-guided HIFU (MRgHIFU) unit, ExAblate 3000, was one of the first to include all 3 of these features and was used for primate feasibility studies in 2006.9 In 2008, McDannold et al. published the first case report in which they described the clinical application of MRgHIFU in 3 patients with GBM; they indicated how multiple focused ultrasound exposures were applied up to the maximum acoustic power available at the time.18 This was the first time a therapeutic ultrasound beam was focused in the human brain through an intact skull, but sufficient power was not available to achieve thermal coagulation of the brain tissue (achieved at temperatures of 55°C or greater). Finally, in 2014, Coluccia et al. reported the use of MRgHIFU to achieve tumor ablation without inducing neurological deficits or other adverse effects in a patient with recurrent GBM.9 Transmission of light energy in LITT results in charred tissue, creating a barrier in cases of large tumors, a characteristic not shared with HIFU.21

Until now, the use of MRgHIFU has been limited to case reports ranging from 1 to 3 people. The most recent clinical trial (NCT01473485; clinicaltrials.gov) seeking to evaluate the safety and feasibility of transcranial MRI-guided focused ultrasound in the treatment of brain tu-
mors is estimated to close in December 2017. Results will hopefully be available in 2018. Provided the safety and efficacy are similar to those shown in the initial case reports, the next steps will entail illustrating survival benefit of MRgHIFU both as a primary therapy in patients with nonresectable lesions and as an adjuvant therapy in those with resectable lesions.

HIFU has also been used in other areas of oncology, including palliation in patients with bone metastases and in the treatment of benign bone tumors, osteoid osteomas, breast cancer, liver cancer, kidney cancer, bladder cancer, and pancreatic cancer.10,15 Pancreatic cancer is the fourth leading cause of cancer deaths in the United States; approximately 53,670 Americans are projected to develop the disease in 2017 (https://seer.cancer.gov/csr/1975_2014/). More than 80% of pancreatic cancer presents as advanced unresectable disease, and the standard treatment options, including chemotherapy, radiotherapy, or both, only achieve a 6- to 12-month survival benefit.12 HIFU ablation has been used as both a primary and a palliative treatment, with initial studies implying survival benefit over supportive care.14,17 Currently, HIFU treatment of pancreatic cancer is widely available in China, with limited availability in South Korea and Europe.22 Sofuni et al. evaluated the therapeutic effect of adding HIFU to current chemotheraphy chemoradiotherapy treatment algorithms in 120 patients with locally advanced and metastatic, unresectable pancreatic cancer being treated at Tokyo Medical University. The median survival period after diagnosis in the HIFU plus chemotherapy group was 997.8 days compared with 366.6 days in the chemotherapy-alone group and 582.7 days in the HIFU-alone group.26 In the latest phase 3 clinical trial in the United States randomly assigning patients to nab-paclitaxel plus gemcitabine (431 patients) or gemcitabine alone (430 patients), the median overall survival durations were only 263.5 and 207.7 days, respectively.27 In prostate cancer, similar HIFU technology has been proposed and used after radiation failure and in conjunction with resection.19 In 2004, Diederich et al. presented a feasibility study of transurethral ultrasound applicators in canine prostate using MRIT.9 In this technology, a balloon catheter encapsulates the transducer to provide coupling and cooling of the urethra and adjacent tissue. The heating pattern can effectively deliver a 180° arch with the ability to control thermal dose, angles, and radius. The initial data related to this therapy demonstrating increased survival in patients with pancreatic and prostate cancer are very promising and our robotically assisted delivery of HIFU is in clinical trials currently.

**Interstitial HIFU**

Although neurosurgical indications for HIFU have focused on extracorporeal devices such as transcranial MRgHIFU, intracavitary interstitial HIFU (also known as catheter-based HIFU) possibilities also are being explored by our laboratory and others in the preclinical setting (Fig. 1). HIFU ablation requires sequential coagulation of small overlapping volumes with multiple, individual, short-time, high-power sonication that cumulatively can cause treatment to last several hours.23 Treatment may be limited
due to patient motion and near-field heating. Interstitial HIFU technology can provide the means to tailor more conformal heating patterns and allow for precise margins regardless of tumor shape, location, and proximity to blood vessels. Furthermore, it allows for the possibility of concurrent biopsy, as well as treatment during the same procedure.

Interstitial HIFU catheters have evolved from initial single-element, noncooled catheters with planar elements to modern multi-elemental, cooled catheters with cylindrical elements. In 2014, N’Djin et al. conducted a study showing feasibility of spatial heating pattern prediction by using a linear ultrasound transducer in a porcine model. Our lab currently utilizes Acoustic MedSystem, Inc.’s TheraVision Ultrasound Ablation System and ACOUSTx applicators, which contain multiple, cylindrical, MRI-compatible transducers that afford multidirectionality for precise shaping of the ablative field and allow for treatment of large tumors. This is achieved by independently activating the transducers along the length of the applicator. Finally, the applicator is encased in a Celcon catheter, which allows degassed water to circulate over the transducers, protecting them from thermal effects, couples the ultrasound energy, and increases thermal penetration into the target volume (https://www.accessdata.fda.gov/cdrh_docs/pdf15/K150019.pdf) (Table 1).

MRI-Guided Robotic Assistance

Without the ability of MRI to provide real-time feedback, HIFU in the brain at this point would not be possible. To streamline performing stereotaxy in the MRI suite, we have administered HIFU in our swine model with an MRI-compatible robotic assistant that allows for positioning the device at our entry point and for alignment of the trajectory. Kocher’s point has been used as our initial entry for proof of concept. Once the alignment is selected, the robotic assistant can then advance the HIFU device to the area being treated from entirely within the bore of the scanner. Robotic movement and imaging may be performed simultaneously, enabling live image-based feedback.

Briefly, the MRgRA and fiducial frame are fixed onto a base platform and placed in the MRI bore, upon which the subject is fixed. The MRgRA has a remote center of motion manipulator that provides for a fixed rotation point with two orthogonal axes, mimicking the arc angles of the stereotactic frame (Fig. 2). Three degrees of freedom (DOF) enable placement of the tip at
the burr hole skull entry point, with the probe at the intended orientation. An additional 2 DOF provide for insertion and rotation of the instrument. The robot is intended to be kinematically similar to a stereotactic frame (Fig. 2). The robot is registered to the MRI scanner coordinate system with a fiducial frame attached to the bottom of the base platform, composed of 9 tubes filled with MRI-visible, high-contrast fluid and configured in a set of Z shapes similar to a standard Cosman-Roberts-Wells frame. Localization of the robot with respect to the imaging system, and thus the animal, was accomplished by using multiple coronal images of the Z-shaped framework. At this point, the pig is moved into the MRI scanner after having undergone burr hole placement and corticotomy in an adjacent sterile room. A set of planning T1-weighted images of the swine is then obtained, with known registration relative to the frame and robot. The neurosurgeon (J.P.) then determines the trajectory and target. After robotic positioning and alignment of the 3 DOF position and 2 DOF orientation, the neurosurgeon introduces a cannula held by the robotic assistant through the corticotomy. The MrgRA then inserts the interstitial HIFU needle through the cannula and images are obtained to confirm placement prior to ablation. Therapy is then guided through MRIT.

The MRI-compatible HIFU probes were designed using multi-element tubular piezoelectric transducers mounted on a hollow polyimide tube. All piezoelectric transducers had 360° directionality and were either 10

---

**TABLE 1. Comparison of SRS, LITT, extracorporeal HIFU, and interstitial HIFU**

<table>
<thead>
<tr>
<th>Feature</th>
<th>SRS</th>
<th>LITT</th>
<th>Extracorporeal HIFU</th>
<th>Interstitial HIFU</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Technology</strong></td>
<td>Delivers targeted radiation using multiple nonparallel beams. Where beams overlap is where the greatest amount of radiation occurs.</td>
<td>Light absorption causes the release of thermal energy to ablate targeted tissue.</td>
<td>Thermal ablation w/ sequential coagulation of small overlapping volumes w/ multiple, individual, short-time, high-power sonications delivered outside of the body.</td>
<td>Thermal ablation targeted therapy that can be delivered interstitially. Applicators are encased to protect surrounding tissue from thermal effects.</td>
</tr>
<tr>
<td><strong>Uses</strong></td>
<td>Gold standard for brain tumor treatment currently in conjunction w/ resection &amp; chemotherapy.</td>
<td>Currently used as a surgical option in essential tremor &amp; epilepsy.</td>
<td>Useful for very small malignant lesions.</td>
<td>Tailors more conformal heating patterns. Allows for precise margins regardless of tumor shape, location, &amp; proximity to blood vessels.</td>
</tr>
<tr>
<td><strong>Benefits</strong></td>
<td>Targeted approach for large, irregularly shaped tumors near critical anatomical structures.</td>
<td>Minimally invasive. Reduced healing time.</td>
<td>Noninvasive.</td>
<td>Allows for the possibility of concurrent biopsy, as well as treatment during the same procedure. Offers increased thermal penetration into target volume.</td>
</tr>
<tr>
<td><strong>Areas of improvement</strong></td>
<td>No biopsy. Conformal patterns for all tumor shapes may be difficult.</td>
<td>May not be used around blood vessels or large hemorrhages. Charring with laser. Invasive.</td>
<td>Treatment may be limited due to patient motion &amp; near-field heating. Treatment can last several hrs. Cannot be used near the skull.</td>
<td>Invasive therapy.</td>
</tr>
</tbody>
</table>

---

![FIG. 2. The Leksell Stereotactic System from Elekta (left) and the robotic manipulator (right) showing motion capabilities. The robotic manipulator is slid into the guiding rails and locked in place with a thumb screw. The robot registration frame is attached to the robot base and does not need to be mounted/unmounted for each procedure.](image-url)
FIG. 3. Triphenyltetrazolium chloride–stained coronal brain slices. The lighter area depicts infarct, and the darker area depicts viable tissue. Area of ablation outlined in the image on the right.

mm (n = 7) or 7 mm (n = 3) long with a 1.5-mm outer diameter. Each transducer had a thermocouple sensor capable of monitoring temperature in real time. A 13-gauge implant catheter was used to insert the HIFU probe, and degassed water circulated through the catheter to prevent the transducer from overheating. HIFU applicators were activated using the FDA-approved TheraVision software system. Our preliminary data determined that energy is delivered at a 4-W acoustic output power over 180 seconds to obtain a 2-cm³ ablation zone (Fig. 3). Work using directional ablative probes is ongoing.

Conclusions

Interstitial HIFU therapy for intracranial tumors utilizes ultrasound technology as a minimally invasive method of tumor ablation. With the concept of a catheter delivery system as the treatment delivery modality, the natural barrier of the calvaria is circumvented. Interstitial HIFU also enables diagnostic capabilities through the cannula and precise conformal tumor ablation. The application of an automated system via a robot improves workflow and efficiency of the delivery system. This treatment system has been shown to work in animal models as a proof of concept.

Acknowledgments

Dr. Pilitsis received grant funding from NIH (1R01CA166379).

References

Disclosures
Dr. Pilitsis is a consultant for Medtronic, Centauri, Boston Scientific, and Abbott; receives grant support from Medtronic, Boston Scientific, Abbott, Nevo, Jazz Pharmaceuticals, and GE Global Research; is a medical advisor for Centauri and Karuna, where she has stock equity; and is on the speakers’ bureau at Boston Scientific and Jazz Pharmaceuticals. Mr. Burdette is the CEO of Acoustic MedSystems, Inc. Mr. Ghoshal is an employee of Acoustic MedSystems, Inc. Mr. Fischer is a consultant for Centauri.

Author Contributions
Conception and design: Pilitsis, MacDonell, Ghoshal, Fischer, Burdette. Acquisition of data: Burdette. Analysis and interpretation of data: Pilitsis. Drafting the article: all authors. Critically revising the article: Pilitsis, MacDonell, Ghoshal, Fischer, Burdette. Reviewed submitted version of manuscript: Pilitsis, MacDonell. Study supervision: Pilitsis.

Correspondence
Julie G. Pilitsis: Albany Medical Center, Albany, NY. pilitsj@mail.amc.edu.